.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The development of a vixarelimab receptor occupancy assay marks a significant advancement in monitoring drug delivery for inflammatory bowel disease (IBD). Recently, researchers detailed a flow cytometry-based approach using colonic pinch biopsies to evaluate target coverage. This method allows clinicians to measure drug-target interactions directly within the affected gut tissues. Consequently, the study provides a vital framework for assessing vixarelimab's ability to bind the Oncostatin M Receptor Beta subunit (OSMR\u03b2). Furthermore, this tissue-based analysis overcomes the limitations of traditional blood-based assessments.
Standard receptor occupancy (RO) assays typically utilize blood samples or single-cell suspensions. However, IBD treatment requires a deeper understanding of drug distribution within solid gut tissues. Developing an assay for colonic biopsies involves complex tissue processing and cell recovery steps. To address these challenges, the team refined techniques to preserve cell viability and receptor integrity. Moreover, they successfully established a protocol that handles the inherent variability of tissue-target interactions. As a result, this assay can accurately quantify how much vixarelimab is bound to its target during clinical trials.
Vixarelimab acts as a monoclonal antibody that inhibits both Oncostatin M (OSM) and Interleukin-31 (IL-31) signaling. These pathways are known to drive inflammation and fibrosis in ulcerative colitis. By using this novel RO assay, investigators can now confirm whether the therapeutic candidate reaches sufficient concentrations in the colon. Therefore, the assay serves as a critical tool for dose optimization in Phase 1c and Phase 2 studies. Since effective target engagement is the cornerstone of clinical success, this progress simplifies the evaluation of new IBD biologics.
The Oncostatin M Receptor Beta (OSMR\u03b2) subunit is part of a signaling pathway that promotes chronic inflammation and tissue remodeling in the gut. Blocking this receptor can help reduce the inflammatory response in patients with ulcerative colitis.
Unlike blood tests that measure systemic drug levels, this tissue-based assay evaluates drug binding directly on cells within the colonic tissue. This provides a more accurate picture of target engagement at the site of the disease.
Receptor occupancy measures the percentage of target receptors bound by a drug. This data helps researchers determine the optimal dose required to achieve a therapeutic effect while minimizing potential side effects.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers developed a flow cytometry-based tissue assay to measure vixarelimab target engagement in colonic biopsies for IBD clinical trials....
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
